Recombinant expression of the β-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 4, 2007, Pages 531-542

  Albrecht, Huguette ^a   Cosman, Monique ^b   Ngu Schwemlein, Maria ^c   Corzett, Michele ^b   Curran, Kena W ^d   Dolan, Cheryl ^b   Fang, Xiangming ^d   DeNardo, Sally J ^a   DeNardo, Gerald L ^a   Balhorn, Rod ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^c WINSTON SALEM STATE UNIVERSITY   (United States)

^d GenWay Biotech Inc   (United States)

Author keywords

Antibody; HLA DR; Lymphoma; Radioimmunotherapy; Radioisotope

Indexed keywords

DETERGENT; HLA DR ANTIGEN; PROTEIN SUBUNIT;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; CELL INCLUSION; CIRCULAR DICHROISM; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN QUATERNARY STRUCTURE; RAJI CELL;

EID: 34548619650     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.375A     Document Type: Article

References (27)

1. Klein J, Sato A. The HLA system: First of two parts. N Engl J Med 2000;343:702.
2. Strominger JL, Wiley DC. The 1995 Albert Lasker Medical Research Award: The class I and II proteins of the human major histocompatibility complex. JAMA 1995;274:1074.
3. Strominger JL, Engelhardt VH, Fuks A, et al. In: Dorf ME, ed. The Role of the Major Histocompatibility Complex in Immunobiology. New York: Garland SPTM, 1981:115.
4. Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830.
5. Rose LM, Gunasekera AH, DeNardo SJ, et al. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1996;43:26.
6. Rose LM, Deng CT, Scott S, et al. Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Mol Immunol 1999;36:789.
7. DeNardo GL. Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective. Semin Oncol 2005;32:27.
8. Balhorn R, Hok S, Burke P, et al. Selective high-affinity ligand (SHAL) "antibody mimics" for cancer diagnosis and therapy: Initial application to lymphoma/leukemia. Clin Cancer Res 2007:in press.
9. Gorga JC, Horejsi V, Johnson DR, et al. Purification and characterization of class II histocompatibility antigens from homozygous human B-cell line. J Biol Chem 1987;252:16087.
10. Merryman P, Gregersen PK, Lee S, et al. Nucleotide sequence of a DRw10 beta chain cDNA clone: Identity of the third D region with that of the DRw53 allele of the beta 2 locus and as the probable site encoding a polymorphic MHC class II epitope. J Immunol 1988;140:2447.
11. Ho SN, Hunt HD, Horton RM, et al. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989;77:51.
12. Lambert C, Leonard N, De B, et al. ESyPred3D: Prediction of proteins' 3D structures. Bioinformatics 2002;18:1250.
13. Murthy VL, Stern LJ. The class II MHC protein HLA-DR1 in complex with an endogenous peptide: Implications for the structural basis of the specificity of peptide binding. Structure 1997;5:1385.
14. Lipman DJ, Pearson WR. Rapid and sensitive protein similarity searches. Science 1985;227:1435.
15. Bolin DR, Swain AL, Sarabu R, et al. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules: Design, structure-activity relationships, and X-ray crystal structures. J Med Chem 2000;43:2135.
16. Smith KJ, Pyrdol J, Gauthier L, et al. Crystal structure of HLA-DR2 (DRA*0101, DRB*1501) complexed with a peptide from human myelin basic protein. J Exp Med 1998;188:1511.
17. Gongora R, Figueroa F, Klein J. Complex origin of the HLA-DR10 haplotype. J Immunol 1997;159:6044.
18. Stern LJ, Wiley DC. The human class II MHC protein HLA-DR1 assembles as empty alpha beta heterodimers in the absence of antigenic peptide. Cell 1992;68:465.
19. Casares S, Bona CA, Brumeanu TD. Engineering and characterization of a murine MHC class II-immunoglobulin chimera expressing an immunodominant CD4 T viral epitope. Protein Eng 1997;10:1295.
20. Boder ET, Bill JR, Nields AW, et al. Yeast surface display of a noncovalent MHC class II heterodimer complexed with antigenic peptide. Biotechnol Bioeng 2005;92:485.
21. Schmidt FR. Recombinant expression systems in the pharmaceutical industry. Appl Microbiol Biotechnol 2004;65:363.
22. Garboczi DN, Hung DT, Wiley DC. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci USA 1992;89:3429.
23. Parker KC, Silver ML, Wiley DC. An HLA-A2/beta 2-microglobulin/peptide complex assembled from subunits expressed separately in Escherichia coli. Mol Immunol 1992;29:371.
24. Zhu Y, Rudensky AY, Corper AL, et al. Crystal structure of MHC class II I-Ab in complex with a human CLIP peptide: Prediction of an I-Ab peptide-binding motif. J Mol Biol 2003;326:1157.
25. Privalov PL. Cold denaturation of proteins. Crit Rev Biochem Mol Biol 1990;25:281.
26. Hato T, Pampori N, Shattil SJ. Complementary roles for receptor clustering and conformational change in the adhesive and signaling functions of integrin alpha IIb beta 3. J Cell Biol 1998;141:1685.
27. Germain RN, Rinker AG, Jr. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature 1993;363:725.